ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Recruiting · NCT07158918 · Registry updated 2025-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-09-08 | NCT07158918 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ABL Bio, Inc. | 3 |
| Merck Sharp & Dohme LLC | 650 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center | Seoul | South Korea | 338 |
| PASO Medical | Frankston | Australia | 3 |
| Samsung Medical Center | Seoul | South Korea | 375 |
| Seoul National University Bundang Hospital | Seongnam | South Korea | 56 |
| Seoul National University Hospital | Seoul | South Korea | 393 |
| UH Cleveland Medical Center | Cleveland | United States | 13 |